Imprimis Pharmaceuticals Stock Shares Owned By Insiders
Imprimis Pharmaceuticals fundamentals help investors to digest information that contributes to Imprimis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Imprimis Stock. The fundamental analysis module provides a way to measure Imprimis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imprimis Pharmaceuticals stock.
Imprimis |
Imprimis Pharmaceuticals Company Shares Owned By Insiders Analysis
Imprimis Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Imprimis Pharmaceuticals Shares Owned By Insiders | 7.16 % |
Most of Imprimis Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imprimis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 7.16% of Imprimis Pharmaceuticals are shares owned by insiders. This is 52.83% lower than that of the sector and 40.28% lower than that of the Shares Owned By Insiders industry. The shares owned by insiders for all United States stocks is 29.04% higher than that of the company.
Imprimis Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imprimis Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imprimis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Imprimis Pharmaceuticals by comparing valuation metrics of similar companies.Imprimis Pharmaceuticals is currently under evaluation in shares owned by insiders category among related companies.
Imprimis Fundamentals
Return On Equity | -153.09 | |||
Return On Asset | -11.94 | |||
Profit Margin | (16.81) % | |||
Operating Margin | (13.94) % | |||
Current Valuation | 120.54 M | |||
Shares Outstanding | 23.28 M | |||
Shares Owned By Insiders | 7.16 % | |||
Shares Owned By Institutions | 23.26 % | |||
Number Of Shares Shorted | 231.01 K | |||
Price To Earning | (2.02) X | |||
Price To Book | 23.40 X | |||
Price To Sales | 2.88 X | |||
Revenue | 37.33 M | |||
Gross Profit | 13.27 M | |||
EBITDA | (3.35 M) | |||
Net Income | (6.28 M) | |||
Cash And Equivalents | 6.24 M | |||
Cash Per Share | 0.27 X | |||
Total Debt | 15.28 M | |||
Debt To Equity | 343.10 % | |||
Current Ratio | 1.13 X | |||
Book Value Per Share | 0.20 X | |||
Cash Flow From Operations | 429 K | |||
Short Ratio | 0.59 X | |||
Earnings Per Share | (0.30) X | |||
Price To Earnings To Growth | (0.13) X | |||
Number Of Employees | 128 | |||
Beta | -0.5 | |||
Market Capitalization | 132.45 M | |||
Total Asset | 14.13 M | |||
Retained Earnings | (57.76 M) | |||
Working Capital | 499 K | |||
Current Asset | 5.87 M | |||
Current Liabilities | 5.37 M | |||
Z Score | 1.2 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Imprimis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Imprimis Pharmaceuticals' short interest history, or implied volatility extrapolated from Imprimis Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Directory Find actively traded commodities issued by global exchanges |